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Summary
Recently the National Institute for Clinical Excellence (NICE) updated its methods guidance for technology
assessment. One aspect of the new guidance is to require the use of probabilistic sensitivity analysis with all cost-
eﬀectiveness models submitted to the Institute. The purpose of this paper is to place the NICE guidance on dealing
with uncertainty into a broader context of the requirements for decision making; to explain the general approach
that was taken in its development; and to address each of the issues which have been raised in the debate about the
role of probabilistic sensitivity analysis in general. The most appropriate starting point for developing guidance is to
establish what is required for decision making. On the basis of these requirements, the methods and framework of
analysis which can best meet these needs can then be identiﬁed. It will be argued that the guidance on dealing with
uncertainty and, in particular, the requirement for probabilistic sensitivity analysis, is justiﬁed by the requirements of
the type of decisions that NICE is asked to make. Given this foundation, the main issues and criticisms raised
during and after the consultation process are reviewed. Finally, some of the methodological challenges posed by the
need fully to characterise decision uncertainty and to inform the research agenda will be identiﬁed and
discussed. Copyright
Introduction
Decisions to adopt, reimburse or issue guidance on
the use of health technologies are increasingly
being informed by an explicit cost-eﬀectiveness
analysis of the alternative interventions [1]. This
requires an analytic framework which can repre-
sent these decision problems explicitly, combine
evidence from a range of sources and facilitate the
extrapolation of costs and eﬀects over time and
between patient groups and clinical settings [2].
Decision analytic modelling provides such a
framework and has become central to the assess-
ment of health technologies by the National
Institute of Clinical Excellence (NICE). The
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importance of decision analytic modelling for
informing decisions about the use of health
technologies is reﬂected in the recently updated
NICE guide on the methods of technology
appraisal [3]. The updated guidance details what
the Institute considers to be appropriate methods
for estimating the cost-eﬀectiveness of technolo-
gies, and for characterising the uncertainty sur-
rounding these estimates. One feature of the
guidance is the development of ‘reference case’
requirements for analysis. As with the recommen-
dations of the Washington Panel in the 1990s [4],
the reference case seeks to increase consistency in
analysis and decision making by deﬁning a set of
methods which should form the basis of any cost-
eﬀectiveness analysis submitted to NICE.
A number of aspects of the NICE guidance have
been controversial [5,6]. The need for probabilistic
sensitivity analysis (PSA) to characterise uncer-
tainty is one such element. The guidance requires
that all estimates of input parameters in a model
be speciﬁed as full probability distributions, rather
than point estimates, to represent the uncertainty
surrounding their values [7–9]. The distributions
employed to describe the uncertainty in individual
parameters are not arbitrary. Rather, the choice of
distribution should be guided by the form of the
data, the type of parameter and the estimation
process. In most cases this would point to only one
or two contending distributions. Most commonly
Monte Carlo simulation is then used to propagate
this parameter uncertainty through the model so
that the imprecision of the cost-eﬀectiveness
results, and hence the decision uncertainty, can be
represented using methods such as cost-eﬀective-
ness acceptability curves [10–12].
The requirement, as part of the reference case,
for the use of PSA to characterise uncertainty has
led to a range of comments and criticisms from,
broadly, two constituencies: those who are more
generally critical of the focus on decision analytic
modelling and decisions based on cost-eﬀective-
ness; and those involved in decision modelling and
economic evaluation. The latter includes those
directly involved in technology assessment for
NICE, and others (inside and outside the UK)
who see that the NICE guidance will have an
impact on what is required for evaluation of heath
technologies internationally. This is an important
and timely and international debate which,
although focused here on the recent NICE
guidance, raises issues which are of much more
general interest, and which have the potential to
aﬀect the future direction and pace of methodo-
logical development in the evaluation of health
technologies.
The purpose of this paper is twofold. Firstly, to
place the NICE methods guidance in general, and
the reference case in particular, in a broader
context and to explain the general approach which
was taken in its development; and, secondly, to
address the main issues which have been raised in
the debate about the role of PSA in particular.
Each of the authors has played a role in
developing the new NICE guidance. The paper is
intended to be an exploration of the issues around
PSA, and a summary of the views of those closely
involved in the production of the guidance.
Background to the guidance
The methods guidance was developed through
four task groups, each dealing with diﬀerent
aspects of assessment and appraisal. The Econom-
ics Task Group developed the guidance which,
among other things, included the speciﬁcation of
the reference case requirements for economic
analysis, the role of decision analytic modelling
and the requirement for PSA. The Economics
Task Group’s draft report was then incorporated
into the full guide by the Methods Working Party,
which included the chairs of all the task groups. It
was then edited and amended in the light of
comments received during a broad consultation
process. The ﬁnal Guide to the Methods of
Technology Appraisal represents the outcome of
this process [3]. Within the Economics Task Group
and the Methods Working Party, there was a
general consensus around the development of the
reference case in general, the importance of
decision modelling and the inclusion of PSA.
General approach
It is important to explain the approach taken by
the Economics Task Group in developing its input
to the document. The most appropriate starting
point for developing methods guidance is to
establish what is required of any analysis seeking
to inform decisions which are consistent with the
objectives of a health care system subject to its
budget constraint. On the basis of these require-
ments, the next step is to identify an appropriate
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framework and methods of analysis which can best
meet these needs.
This means that the guidance is not prescriptive
about particular methods; rather it sets out what is
required of an analysis. However, the requirement
for the analysis to be predicated on the needs of
the decision making process was prescriptive [3].
The guidance did not start from the point of
current capacities, current practice or consensus.
In fact, it was part of the Economics Task Group’s
brief to encourage the use of appropriate methods
rather than simply to reﬂect current practice in the
ﬁeld. Issues associated with the current capacity
and resourcing of the academic groups under-
taking technology assessment for NICE, and the
implications for submissions from stakeholders,
was not regarded as a constraint on the discussions
and recommendations of the task group. Rather,
these issues would be dealt with elsewhere in
negotiation between the Department of Health,
NICE, the technology assessment groups and
sponsors. It was also understood that developing
methods guidance would be a continual process
with periodic updates leading to further revisions
at some point in the future, reﬂecting the on-going
methodological development in the ﬁeld. It was
also suggested by the task group that more
detailed technical guides on key aspects of the
guidance, such as evidence synthesis, decision
analytic modelling and PSA, should be developed
to provide further support and methodological
guidance.
The reference case
This general approach to the development of
the guidance underpinned our adoption of the
reference case analysis. The justiﬁcation for a
reference case is the same as that of the Washing-
ton Panel which was set up by the US Public
Health Service to advise on ‘good practice’ in the
ﬁeld [4]. The Washington Panel’s reasoning was
that if economic evaluation is to inform resource
allocation decisions in health care, then a common
and agreed analytic framework and set of methods
is required which facilitates comparability. How-
ever, over prescription and the imposition of
stiﬂing orthodoxy in a fast developing ﬁeld needs
to be avoided. The primary purpose of the NICE
reference case is, therefore, to ensure that the
requirements for decision making within the NICE
remit are met as far as possible by specifying those
methods which meet these needs.
A second purpose of the reference case is to
provide some degree of comparability within the
appraisal of a particular technology, between the
submissions from stakeholders and the indepen-
dent technology assessment report. The lack of
comparability between submissions within an
appraisal and the wide range of estimates of
cost-eﬀectiveness presented, without clear expla-
nation of these diﬀerences, has been a constant
problem for the Appraisal Committee and the
assessment teams [13]. As well as comparability
within an appraisal, the reference case was also
intended to provide comparability between
appraisals of diﬀerent technologies and over time,
thus contributing to consistency in decision
making.
However, it is not the purpose of the reference
case to limit the methods that can be used as part
of a technology assessment or stakeholder sub-
mission. It is explicitly recognised that additional
non-reference case analyses may be appropriate.
Indeed, such analyses are positively encouraged as
long as they are clearly justiﬁed, and any
diﬀerences in cost-eﬀectiveness results fully ex-
plained. The methods guidance makes clear that,
in its considerations, the Appraisal Committee
will not necessarily regard the reference case as
providing the ‘best’ analysis, for a particular
technology, but will consider the justiﬁcations
for any non-reference case analysis in coming
to a view about the most reliable estimates of
cost-eﬀectiveness. There is also a recognition in
the guidance that in some circumstances a
complete reference case analysis may not be
possible for a variety of reasons. For example, in
some instances, the data required to present
reference case results may not be available or
there may be other barriers (including computa-
tional challenges) to applying reference case
methods. In these cases, the reasons for a failure
to provide a full reference case analysis should be
clearly explained, and the likely implications
should, as far as possible, be quantiﬁed so that
the Appraisal Committee can decide what weight
it will attach to the results.
So the general approach to developing the
guidance and specifying the reference case was to
balance the need for comparability within and
between appraisals with the desire to avoid being
overly prescriptive about methods. It was antici-
pated that, in some appraisals, a well-justiﬁed
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non-reference case analysis will be regarded as
providing the best estimates of cost-eﬀectiveness.
Therefore, it is important to see the guidance in
general, and on PSA in particular, in the context of
this overall approach, the purposes of the refer-
ence case and the consideration of a justiﬁed non-
reference case analysis.
Dealing with uncertainty
The guidance states that ‘it is important for
the Appraisal Committee to know about the
uncertainty associated with clinical and cost
eﬀectiveness information’ (p. 20) [3]. Nevertheless,
there are strong arguments for basing decisions
about resource allocation on expected cost-eﬀec-
tiveness rather than the traditional and arbitrary
rules of inference [14]. This had led a number of
commentators to suggest that this makes the
consideration of uncertainty and the use of PSA
redundant. However, decision making based on
expected utility (in this context expected net
beneﬁt) in no way implies that decision uncertainty
is unimportant. Indeed, an assessment of the
implications of decision uncertainty is an essential
part of a decision making process that is consistent
with objectives and constraints of any health care
system [14].
An honest and transparent characterisation of
the uncertainty is needed for a number of reasons.
Firstly, NICE does make recommendations about
further research, and can issue guidance which is
conditional on additional evidence being provided
[15], on the conduct of pilot studies before wider
adoption [16] or on a technology only being used
within a clinical trial [17]. Secondly the date when
the guidance will be reconsidered must be speciﬁed
which may well be informed by the uncertainty
surrounding the decision and the anticipation of
further evidence being available in the future.
Finally, the Appraisal Committee requires some
means of assessing the costs associated with a
possible change in the decision about a technology
in the future (e.g. about the consequences of
irreversibility) and about the impact on ongoing
research of issuing guidance.
In principle, many of these issues could be
formally addressed using value of information
analysis [14–18] and real options pricing [19].
However, these formal approaches were not
speciﬁed as part of the reference case although
value of information analysis was recommended.
Nevertheless, some assessment of whether existing
evidence is suﬃcient to support the use of a
technology, the appropriate length of time until
the reconsideration of the guidance and the
implications of irreversibility when costs and
eﬀects of a decision are uncertain must be made
as part of any decision making process. The issue
is one of who should be responsible for such an
assessment. The opinion of the task group was
that, at the present time, these assessments should
be made by the Appraisal Committee supported
by NICE, and not necessarily by the analysts
making submissions to the Institute. Since these
assessments can only be made on the basis of a
clear and transparent characterisation of decision
uncertainty, the focus of the guidance was on the
use of PSA to provide this characterisation.
Finally, it should also be recognised that, for
decision models in which there is a non-multi-
linear relationship between inputs and outputs
(e.g. Markov models), the correct calculation of
expected costs and eﬀects will need the full
uncertainty around parameters to be expressed.
Therefore, probabilistic analysis of the model also
ensures adequate estimates of expected cost and
eﬀects.
Probabilistic sensitivity analysis
The following discussion focuses on those com-
ments and arguments regarding PSA that have
been made during the consultation process, and
which have been raised elsewhere in discussion
about the implementation of the NICE methods
guidance.
The necessity of PSA
If the characterisation of decision uncertainty is
required for decision making, then the question is
whether PSA is the most appropriate framework
to achieve this. For example, it has been suggested
that in many cases a simple series of one-way
sensitivity analyses may be suﬃcient [20]. How-
ever, simple sensitivity analysis cannot provide
enough insight into the scale of decision uncer-
tainty. There is a strong incentive for manufac-
turers, when submitting cost-eﬀectiveness models
to NICE, to claim that their sensitivity analyses
show their conclusions are robust to parameter
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uncertainty. In many models, the uncertainty in
the individual parameters may be very unlikely to
change a decision (i.e. the value of additional
information for individual parameters can be
zero). In combination with the other parameters,
however, a complete picture of the parameter
uncertainty in the model may generate consider-
able decision uncertainty and the value of addi-
tional information may be very high.
The way to understand the implications for
decision uncertainty of imprecisely estimated
parameters is to include all of those parameters
subject to uncertainty in the sensitivity analysis,
and to use the full distributions of those para-
meters based on all available evidence. This is not
possible with simple one-way sensitivity analysis.
Although multi-way sensitivity analysis is some-
times used to explore combined uncertainty, with a
large number of parameters this can be markedly
more time- and computer-intensive than PSA.
More importantly, it is generally very diﬃcult to
interpret correctly and becomes impossible if some
parameters are correlated. For example, the
statistical estimation of parameters, often requir-
ing methods of evidence synthesis [21], generates
complex correlation structures between para-
meters which makes it impossible to locate a
ﬁxed (set of) parameter value(s) which can be
regarded as ‘extreme’. The Economics Task
Group was clear that one-way sensitivity
analysis will underestimate decision uncertainty,
and that a well conducted PSA will engender a
more realistic representation of uncertainty in a
model’s results.
It was recognised that, in making an assessment
of the implications of decision uncertainty when
issuing guidance, the Appraisal Committee will
also need an understanding of the contribution of
speciﬁc parameters (or combinations of para-
meters). This contribution to decision uncertainty
can be assessed by using value of information
methods for individual and groups of parameters
[22]. Indeed, these methods are recommended in
the guidance but were not made part of the
reference case for the reasons given above.
Additional assumptions of PSA
Some commentators have criticised PSA on the
grounds that it introduces further assumptions
into the decision model. In particular, the choice of
distribution to represent uncertainty and the
common assumption of independence between
parameters have been identiﬁed as limitations of
the probabilistic approach [23].
A large number of potential distributions are
available within commonly used modelling
packages, and this may be seen to reinforce the
apparently arbitrary choice of distribution. How-
ever, if the principle of using the standard
statistical approach to the estimation of a para-
meter is followed, such that the distribution
employed reﬂects the statistical uncertainty in that
parameter’s estimation, then typically only one or
two distributional forms are candidates. For
example, probability parameters are bounded on
the interval zero-one, so it would be inappropriate
to specify a distribution that gave a non-negligible
probability to obtaining a parameter value outside
of that range. With this in mind, the appropriate
choice of distribution will be closely related to the
nature of the parameter, the form of the data and
the method of estimation. Where a probability
parameter is estimated from a proportion, the beta
distribution (which is bounded zero-one) is the
natural choice of distribution. However, if the
probability parameter is estimated from a logistic
regression, then the parameters of interest are the
coeﬃcients on the log-odds scale and multivariate
normality on this scale would be the appropriate
assumption. For probabilities estimated from
time-to-event data, the parameters would be the
coeﬃcients from a survival analysis estimated on
the log hazard scale and, again, the appropriate
assumption would be multivariate normality on
this scale. Application of this general approach to
using the distributional form that relates to the
estimation of the parameter of interest is likely to
make the depiction of uncertainty in PSA less
arbitrary than one-way sensitivity analysis rather
than more arbitrary.
While it is true that examples of PSA often
assume independence between parameters, it
is not a requirement of the approach. The use
of multivariate normal distributions is common
in regression analysis and illustrates a situation
where the covariance between parameters
can easily be estimated from the covariance
matrix. Where regression analyses inform the
estimation of parameters in a decision model,
therefore, it is clearly appropriate that correlations
between regression coeﬃcients are included in
that model and methods exist to allow the
correlation of parameters in the multivariate
normal case.
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Computational burden of PSA
An important area of discussion regarding the role
of PSA has been in the context of micro
simulation. This type of model can be particularly
useful for modelling diseases where patients’ future
prognoses are strongly time-dependent or are
inﬂuenced by earlier events. In such models the
progress of individual patients through the model
is simulated in order to allow for a patient’s case
history in the model to impact the probability of,
or the time until, future events. In order to
characterise decision uncertainty, a second level
of simulation is required and this would, for some
models, require considerable computation time.
This problem is accentuated by the tight time
constraints which exist for NICE appraisals which,
in particular, limit the technology assessment
groups in developing their analyses.
The choice about model structure and complex-
ity is always a trade-oﬀ between descriptive
realism and tractability in terms of computational
burden and data requirements. The key issue is
whether the model is suﬃciently realistic to inform
the decision. Some research has been undertaken
to compare micro-simulation and cohort models
[24]. However, identifying the ‘best model’ for a
given appraisal is diﬃcult. More research is
required to develop criteria for selecting an
appropriate structure for a decision model given
available evidence on disease prognosis and the
impact of alternative interventions.
Until such research is undertaken, the selection
of an appropriate model structure will have to be
based on a careful balance between a reasonable
simpliﬁcation of reality and computational and
data burden. It is likely that micro-simulation will
play a continued role in some technology assess-
ments where there is a need to incorporate
evidence of the impact of patients’ histories in a
way that simply cannot be captured in more simple
cohort models. Nevertheless, given the importance
of decision uncertainty for the Appraisal Commit-
tee’s deliberations, it seems reasonable for NICE
to expect PSA to be undertaken. Some micro-
simulation models will be limited in complexity
and number of parameters, and PSA will not be
computationally expensive. For more complex
models, methods have recently been described
which can avoid two-level simulation, cutting
down on computation time [25]. Indeed, these
methods have been used in a recent technology
assessment for NICE [26]. In those situations
where a mixture of time constraints and model
complexity preclude the implementation of PSA, a
non-reference case analysis might be justiﬁed
on the basis that a micro-simulation was the best
means of structuring the decision problem
appropriately.
Presenting and interpreting probabilistic
analysis
Several methods have been discussed and used to
present the results of PSA, many of which have
been developed in the context of stochastic
analysis of patient-level data, usually from rando-
mised trials [27]. In the updated NICE methods
guidance, the use of cost-eﬀectiveness acceptability
curves (CEACs) is recommended. These present
the probability that (proportion of simulations in
which) a given intervention is more cost-eﬀective
than the alternatives for a range of maximum
thresholds regarding NICE’s willingness to pay for
an additional QALY [10–12]. Some have argued
that non-specialists on the Appraisal Committee
ﬁnd the CEAC diﬃcult to interpret and that the
presentation of the joint uncertainty in diﬀerential
costs and eﬀects on the cost-eﬀectiveness plane [28]
is more intuitive. However, NICE appraisals
increasingly require the comparison of several
interventions. As a means of comparing the cost-
eﬀectiveness of more than two competing options,
the cost-eﬀectiveness plane becomes impossible to
interpret correctly. NICE is embarking on a series
of training sessions for the Appraisal Committees,
including a session on the methods of presenting
the results of PSA.
It is true, however, that a standard CEAC does
not contain a decision rule; that is, it will not in
itself suggest the ‘best intervention’. This is
because the intervention with the highest prob-
ability of being cost-eﬀective is not always the one
with the highest expected (i.e. mean) cost-eﬀec-
tiveness. The reason for this is that the distribu-
tions of costs and eﬀects are often asymmetrical
and is analogous to the diﬀerence between the
median and a mean of a standard frequency
distribution based on patient-level data. The
concept of the cost-eﬀectiveness frontier has been
presented as a way of overcoming this problem
[12], where the intervention on the frontier is
always the one with the highest expected cost-
eﬀectiveness.
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Hence the Economics Task Group took the view
that the CEAC is the best way of communicating
decision uncertainty, particularly when more than
two options are being compared. Other ways of
presenting the uncertainty in an analysis are not
precluded, however. As described above, a key
advantage of PSA is that, by quantifying decision
uncertainty, it can help prioritise future research,
and the CEAC together with an appropriate
frontier has a direct association with the expected
value of perfect information [12]. This is particu-
larly important given that NICE has recently
appointed a Research and Development Advisory
Committee and that it is thinking more carefully
about the appropriate dates on which to
consider the revision of guidance about particular
technologies, and about research recommenda-
tions.
Handling other sources of uncertainty and sub-
group variability
It is explicitly recognised in NICE’s updated
methods guidance [3] that the uncertainty sur-
rounding parameter estimates is not the only
source of uncertainty in a cost-eﬀectiveness model.
As noted above, an important source of uncer-
tainty relates to the assumptions regarding the
structure of the model. In addition, the appro-
priate interpretation of evidence, given its variable
quality and likely heterogeneity, is another source
of uncertainty. In principle, these types of un-
certainty can be handled as part of the PSA by
ascribing probabilities to alternative assumptions
about model structure to reﬂect the analysts’ or the
Appraisal Committee’s views about their appro-
priateness. An alternative approach, and the one
favoured in the methods guidance, is to conduct
scenario analysis where the probabilistic analysis is
run several times, each scenario conditional on
diﬀerent assumptions about model structure or
interpretations of the available evidence. The
Appraisal Committee is then responsible for
making an assessment of which of the scenarios
is the most credible.
The issue of how to deal with possible variation
in cost-eﬀectiveness between patient sub-groups
was also considered in the updated guidance. This
is an important issue given NICE’s objective to
maximise health gain from available resources. If
available evidence suggests that there is variability
between sub-groups in one or more parameters,
which could lead to important variation in cost-
eﬀectiveness, and where sub-groups can be ade-
quately identiﬁed in routine clinical practice before
management decisions are taken, then this should
be dealt with using sub-group analysis. That is,
separate estimates of cost-eﬀectiveness should be
presented for each sub-group, in a manner
analogous to scenario analysis for structural
uncertainty and interpretation of evidence. How-
ever, the use of sub-group analysis emphasises why
PSA is so important for decision making. This is
because one implication of ‘dividing up’ the
available evidence into speciﬁc sub-groups is that
the samples become smaller and, all things being
equal, the sub-group-speciﬁc estimates of para-
meters are less precise than the group-level
estimates. Hence, although expected cost-eﬀective-
ness may show a degree of variation between sub-
groups that is considered relevant for decision
making, the implications for decision uncertainty
should not be ignored, particularly in terms of
recommendations for future research.
Conclusions
The purpose of this paper is to explain the
rationale for making PSA part of the reference
case for NICE appraisal. It is hoped that there will
be greater acceptance of PSA given the explana-
tion of how it was seen to ﬁt with the requirements
for NICE decision making. There are some good
examples of PSA in the literature to provide a
guide to the technical implementation of the
methods [9,13,29] [Palmer S, Sculpher M, Philips
Z et al. Management of non-ST-elevation acute
coronary syndromes: how cost-eﬀective are glyco-
protein IIb/IIIa antagonists in the UK National
Health Service? Int J Cardiol, in press, Briggs A,
Sculpher M, Dawson J, FitzPatrick R, Murray D,
Malchau H. The use of probabilistic decision
models in technology assessment: the case of hip
replacement. J Appl Health Econ Policy, in press].
Increasingly these methods are being seen in
manufacturers’ submissions to NICE and in the
models developed by the assessment teams. More
detailed technical guides are likely to emerge from
NICE to provide greater clarity about the use, and
critical appraisal, of PSA. In due course, the
methods guidance itself will be updated, and this is
likely to reﬂect the continued development of
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methods of cost-eﬀectiveness. However, the need
to quantify the implications of the imprecision in
parameter estimates for decision uncertainty is
likely to remain.
There are, of course, many challenges when
attempting to estimate costs and eﬀects across a
range of possible interventions, over a relevant
time horizon and for speciﬁc patient groups, while
attempting fully to represent the uncertainty
surrounding the decision. The issues of interpreta-
tion of evidence, synthesis, potential bias, exchan-
geability and appropriate model structure have
always been present in any informal and partial
review of evidence. In fact, until quite recently,
these challenging issues could be conveniently
ignored by both policy makers, clinicians and
analysts while decision making was opaque and
based on implicit criteria and unspeciﬁed
‘weighing’ of the evidence. These challenges must
be faced as more explicit and transparent ap-
proaches to decision making are being taken.
Indeed, one of the many advantages of taking a
more transparent and explicit approach to deci-
sion making and the characterisation of uncer-
tainty is that it exposes many important
methodological issues which have previously been
avoided by presenting partial analysis which do
not directly address the decisions which must be
made in any health care system.
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